Abstract
In the group of 63 children in whom a relapse of ALL after first suspension of treatment occurred, and in whom a repeated cessation of therapy had place, 46.2% of patients had probability of a prolonged symptomless survival. The children with an isolated extramedullary relapse had a greater chance for a DFS of 7 years, than those with a relapse in the bone marrow (p = 0.05). The patients with a relapse occurring after the first cessation of treatment of ALL should be treated as intensively as newly diagnosed cases, because they have a real possibility for a prolonged survival during remission phase of disease.
Publication types
-
Clinical Trial
-
Comparative Study
-
English Abstract
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asparaginase / administration & dosage
-
Child
-
Child, Preschool
-
Cyclophosphamide / administration & dosage
-
Daunorubicin / administration & dosage
-
Female
-
Humans
-
Infant
-
Male
-
Methotrexate / administration & dosage
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / mortality
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Prednisone / administration & dosage
-
Remission Induction
-
Time Factors
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Cyclophosphamide
-
Asparaginase
-
Prednisone
-
Methotrexate
-
Daunorubicin
Supplementary concepts
-
LSA2-L2 protocol
-
PVDA protocol